Trinity Biotech

Trinity Biotech Stock-Based Compensation

The Stock-Based Compensation (SBC) of Trinity Biotech (TRIB) as of Oct 16, 2026 is 324,000.00 USD. In the previous year, Stock-Based Compensation (SBC) was 1.32 M USD — a change of -75.38% (lower).

Stock-Based Compensation

324,000.00USD

YoY

-75.38%

Last updated:

Stock-Based Compensation (SBC) of Trinity Biotech is 2025 324,000.00 USD. Stock-Based Compensation (SBC) of Trinity Biotech was 2024 1.32 M USD. It decreases by -75.38% lower compared to the previous year.

The Trinity Biotech Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
1.37 M USD
Jan 1, 2019
758,000.00 USD
Jan 1, 2020
792,000.00 USD
Jan 1, 2021
1.10 M USD
Jan 1, 2022
1.76 M USD
Jan 1, 2023
2.07 M USD
Jan 1, 2024
1.32 M USD
Jan 1, 2025
324,000.00 USD
The Trinity Biotech Stock-Based Compensation history
YEARStock-Based CompensationYoY
324,000.00USD-75.38%
1.32 MUSD-36.39%
2.07 MUSD+17.89%
1.76 MUSD+59.55%
1.10 MUSD+38.89%
792,000.00USD+4.49%
758,000.00USD-44.63%
1.37 MUSD+47.52%
928,000.00USD-34.37%
1.41 MUSD-8.77%
1.55 MUSD+3.61%
1.50 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Stock-Based Compensation (SBC) of Trinity Biotech is 324,000.00 USD in 2025.

Stock-Based Compensation (SBC) of Trinity Biotech changed from 1.32 M USD to 324,000.00 USD, representing a -75.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Trinity Biotech

All Key Metrics — Trinity Biotech